35 reports of this reaction
3.2% of all MENTHOL, METHYL SALICYLATE reports
#4 most reported adverse reaction
APPLICATION SITE ERYTHEMA is the #4 most commonly reported adverse reaction for MENTHOL, METHYL SALICYLATE, manufactured by Hisamitsu Pharmaceutical Co., Inc.. There are 35 FDA adverse event reports linking MENTHOL, METHYL SALICYLATE to APPLICATION SITE ERYTHEMA. This represents approximately 3.2% of all 1,107 adverse event reports for this drug.
Patients taking MENTHOL, METHYL SALICYLATE who experience application site erythema should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
APPLICATION SITE ERYTHEMA is moderately reported among MENTHOL, METHYL SALICYLATE users, representing a notable but not dominant share of adverse events.
In addition to application site erythema, the following adverse reactions have been reported for MENTHOL, METHYL SALICYLATE:
The following drugs have also been linked to application site erythema in FDA adverse event reports:
APPLICATION SITE ERYTHEMA has been reported as an adverse event in 35 FDA reports for MENTHOL, METHYL SALICYLATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
APPLICATION SITE ERYTHEMA accounts for approximately 3.2% of all adverse event reports for MENTHOL, METHYL SALICYLATE, making it a notable side effect.
If you experience application site erythema while taking MENTHOL, METHYL SALICYLATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.